東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Neuropsychological performance of sy...

Elliott, Darlyne.

Linked to FindBook

Google Book

Amazon

博客來

Neuropsychological performance of systemic lupus erythematosus patients treated with DHEA: A double-blind crossover pilot study.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Neuropsychological performance of systemic lupus erythematosus patients treated with DHEA: A double-blind crossover pilot study./
Author:	Elliott, Darlyne.
Description:	278 p.
Notes:	Adviser: Amy M. Wisniewski.
Contained By:	Dissertation Abstracts International66-08B.
Subject:	Health Sciences, Immunology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3186966
ISBN:	9780542289149

Neuropsychological performance of systemic lupus erythematosus patients treated with DHEA: A double-blind crossover pilot study.
Elliott, Darlyne.

Neuropsychological performance of systemic lupus erythematosus patients treated with DHEA: A double-blind crossover pilot study. - 278 p.

Adviser: Amy M. Wisniewski.

Thesis (Ph.D.)--Pacific Graduate School of Psychology, 2005.

Neuropsychiatric systemic lupus erythematosus (NP-SLE) is a systemic autoimmune disease which includes central nervous system (CNS) involvement. NP-SLE, as well as SLE, patients have high rates of cognitive impairment, such as, problems with attention and concentration, memory and learning, and complaints about not being able to "think clearly." The mechanisms underlying cognitive dysfunction have been unclear. Dehydroepiandrosterone (DHEA) is an abundant adrenal hormone that has been demonstrated to have good tolerance in humans. It has been used successfully in clinical trials to treat the disease manifestations of SLE. This pilot study is the first of its kind to investigate the effects of DHEA for improving cognitive dysfunction in NP-SLE patients.

ISBN: 9780542289149Subjects--Topical Terms:

1017716
Health Sciences, Immunology.

Neuropsychological performance of systemic lupus erythematosus patients treated with DHEA: A double-blind crossover pilot study.
LDR:03306nam 2200325 a 45 001 970612
005 20110921
008 110921s2005 eng d
020 $a 9780542289149
035 $a (UMI)AAI3186966
035 $a AAI3186966
040 $a UMI $c UMI
100 1 $a Elliott, Darlyne. $3 1294651
245 1 0 $a Neuropsychological performance of systemic lupus erythematosus patients treated with DHEA: A double-blind crossover pilot study.
300 $a 278 p.
500 $a Adviser: Amy M. Wisniewski.
500 $a Source: Dissertation Abstracts International, Volume: 66-08, Section: B, page: 4507.
502 $a Thesis (Ph.D.)--Pacific Graduate School of Psychology, 2005.
520 $a Neuropsychiatric systemic lupus erythematosus (NP-SLE) is a systemic autoimmune disease which includes central nervous system (CNS) involvement. NP-SLE, as well as SLE, patients have high rates of cognitive impairment, such as, problems with attention and concentration, memory and learning, and complaints about not being able to "think clearly." The mechanisms underlying cognitive dysfunction have been unclear. Dehydroepiandrosterone (DHEA) is an abundant adrenal hormone that has been demonstrated to have good tolerance in humans. It has been used successfully in clinical trials to treat the disease manifestations of SLE. This pilot study is the first of its kind to investigate the effects of DHEA for improving cognitive dysfunction in NP-SLE patients.
520 $a The objective of this double-blind, placebo-controlled study was to investigate the effects of DHEA on the neuropsychological performance of patients in the cognitive domains of Attention/Concentration, Memory/Learning, and Reasoning/Executive Functions. Twenty NP-SLE outpatients received either DHEA (200mg/day) or placebo for one month in a crossover design. All patients underwent neuropsychological testing at baseline and at the end of the one month trial period of DHEA or placebo.
520 $a The results of this study indicated that some patients neuropsychological performance in the domain of Memory and Learning improved after DHEA treatment compared to placebo treatment. The group of patients that received DHEA the first month and placebo the second month showed significant improvement in neuropsychological performance after DHEA treatment; however, the group that received placebo first and DHEA second had improved performance but it was not statistically significant. No significant differences for treatment were found on neuropsychological performance in the domains of Attention/Concentration or Reasoning/Executive Functions.
520 $a These results suggest that DHEA treatment may have beneficial effects for the treatment of cognitive dysfunction in memory and learning. However, some patients may manifest increased depressive symptoms from direct or indirect DHEA effects. Further clinical trials with larger samples, with participants in different age categories, and with greater racial/ethnic diversity are needed.
590 $a School code: 0621.
650 4 $a Health Sciences, Immunology. $3 1017716
650 4 $a Psychology, Cognitive. $3 1017810
650 4 $a Psychology, Physiological. $3 1017869
690 $a 0633
690 $a 0982
690 $a 0989
710 2 0 $a Pacific Graduate School of Psychology. $3 1034270
773 0 $t Dissertation Abstracts International $g 66-08B.
790 $a 0621
790 1 0 $a Wisniewski, Amy M., $e advisor
791 $a Ph.D.
792 $a 2005
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3186966